EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Product updates
Kapoose Creek Bio advances two potential AI-powered neurological drug compounds
AI Drug Discovery
May 30, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Product updates
Partnerships
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
AI Drug Discovery

AI Drug Discovery

May 30, 2024

Kapoose Creek Bio advances two potential AI-powered neurological drug compounds

Product updates

  • AI-powered nature-derived drug developer Kapoose Creek Bio has identified two potential lead compounds for neurological diseases and mental health conditions. The company is currently optimizing these compounds through human dosing, with the goal of creating a preclinical drug candidate.

  • The two compounds, KCB-100 and KCB-200, were extracted from the biotech firm's collection of cultivated and conserved fungi, and have reportedly exhibited potent neuroplastic and neuroprotective activities. The company will leverage its AI platform, unEarth Rx, to isolate and optimize compounds extracted from nature and expedite the drug discovery process.

  • Kapoose Creek Bio specializes in leveraging AI to discover small-molecule medicines from nature. The company focuses on identifying and developing novel therapeutic compounds derived from cultivated fungal sources. Utilizing its proprietary unEarth Rx platform, Kapoose integrates phenotypic screening with advanced ML to accelerate the identification of drug leads. The company’s studies target several therapeutic areas, including neuroscience, cancer, and infectious diseases​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.